Four European venture capital funds have contributed to a $43m (€49.3m) financing for Agensys, a US biotechnology firm, in a deal highlighting the sector's popularity.

In one of the largest venture capital financings this year, European investors HBM, Lombard Odier, Carnegie and BSI joined a syndicate of 10 institutional investors in the private placing for Agensys, which develops cancer treatments.